The Chhattisgarh health department is upholding its commitment to zero tolerance on quality control, leading to the issuance of a blacklisting show cause notice to M/s. Effi Parenterals. This action comes in response to significant irregularities discovered in the quality of medicines supplied.
Before distribution to health institutions, the CGMSCL mandates thorough quality testing of drug batches from suppliers. These tests are conducted in NABL-accredited labs, guaranteeing only approved drugs are supplied to medical facilities.
The specific issue involves Albendazole Tablets IP 400 mg (Drug Code – D12) supplied by Effi Parenterals. The batches PGT25451, PGT25450, PGT25480, and PGT25229, failed quality tests at the State Drug Testing and Research Laboratory, Raipur, before distribution to hospitals. Consequently, the firm faces a show-cause notice and potential blacklisting, in alignment with the department’s stringent zero-tolerance policy on drug quality. The firm has also been directed to recall all failed drug batches from its warehouses.
Prior to this, the firm provided 14 batches of Albendazole Tablets IP 400 mg which were cleared for distribution after successfully passing the NABL tests.